logo
Plus   Neg
Share
Email

Lundbeck To Buy Alder BioPharma In $1.95 Bln Deal - Quick Facts

H. Lundbeck A/S agreed to buy Alder BioPharmaceuticals (ALDR) in a transaction valuing the company at up to US$1.95 billion or about DKK 13 billion net of cash, on a fully diluted basis.

As per the terms of the deal, Lundbeck will commence a tender offer for all outstanding shares of Alder, whereby Alder stockholders will be offered an upfront payment for US$18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional US$2.00 per share upon approval of eptinezumab by the European Medicines Agency (EMA), representing a total potential consideration of US$20.00 per share.

The transaction is expected to be core earnings per share accretive in 2023 assuming FDA approval in the first quarter of 2020 followed by regulatory approvals in other regions including Europe.

The transaction is expected to close in the fourth quarter of 2019, subject to customary closing conditions, including the tender of more than 50% of all shares of Alder outstanding at the expiration of the offer and receipt of required regulatory clearances, which includes a Hart-Scott-Rodino review in the U.S.

Lundbeck expects to fund the acquisition through existing cash resources and bank financing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
Follow RTT